

Supplementary Materials




Figure S1. The interaction diagram between the DLK in complex with inhibitor 2-((6-(3,3-difluoropyrrolidin-1-yl)-4-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)amino)isonicotinonitrile (PDB ID: 5ceo) and 2-[[6-[3,3-bis(fluoranyl)pyrrolidin-1-yl]-4-[1-(oxetan-3-yl)piperidin-4-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile (Chemical ID: 50D). (A) Molecular docking between the protein (PDB IDWx: 5ceo) and compound (Chemical ID: 50D). (B) Local two

dimensional display of the interaction diagram between the protein (PDB ID: 5ceo) and compound (Chemical ID: 50D).

Table S1. Results of molecular (kinase inhibitor) docking and predicted result by CSConv2d and DEEPScreen.

Target	Drug ID	Affinity (kcal/mol)	RMSD	Pred (CSConv2d)	Pred (DEEPScreen)	Label
mTOR	DB00877	-18.0	0.3764	1	1	1
	DB11651	-12.1	-	1	1	1
	DB13109	-11.0	-	1	0	1
	DB12986	-8.2	-	1	0	1
	DB12400	-7.6	-	1	0	1
VEGFR	DB07334	-9.1	1.3344	1	0	1
	DB06595	-10.3	-	1	1	1
	DB11977	-9.3	-	0	1	1
	DB14765	-8.0	-	1	0	1
	DB05608	-7.9	-	1	0	1
JAK	DB08895	-8.9	1.2841	1	1	1
	DB11763	-8.7	-	0	0	1
	DB12154	-8.4	-	1	1	1
	DB11817	-7.5	-	0	1	1
	DB14973	-6.8	-	1	0	1